JOP20190143A1 - Small molecule inhibitors of the jak family of kinases - Google Patents
Small molecule inhibitors of the jak family of kinasesInfo
- Publication number
- JOP20190143A1 JOP20190143A1 JOP/2019/0143A JOP20190143A JOP20190143A1 JO P20190143 A1 JOP20190143 A1 JO P20190143A1 JO P20190143 A JOP20190143 A JO P20190143A JO P20190143 A1 JOP20190143 A1 JO P20190143A1
- Authority
- JO
- Jordan
- Prior art keywords
- kinases
- small molecule
- molecule inhibitors
- jak family
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease. FIG.1
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662435609P | 2016-12-16 | 2016-12-16 | |
US201762592680P | 2017-11-30 | 2017-11-30 | |
US201762596607P | 2017-12-08 | 2017-12-08 | |
PCT/US2017/066744 WO2018112379A1 (en) | 2016-12-16 | 2017-12-15 | Small molecule inhibitors of the jak family of kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
JOP20190143A1 true JOP20190143A1 (en) | 2019-06-13 |
JOP20190143B1 JOP20190143B1 (en) | 2023-09-17 |
Family
ID=61692222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0143A JOP20190143B1 (en) | 2016-12-16 | 2017-12-15 | Small molecule inhibitors of the jak family of kinases |
Country Status (34)
Country | Link |
---|---|
US (5) | US10294226B2 (en) |
EP (2) | EP3555097B1 (en) |
JP (2) | JP7291077B2 (en) |
KR (1) | KR102352462B1 (en) |
CN (1) | CN110088105B (en) |
AU (3) | AU2017377069B2 (en) |
BR (1) | BR112019011968A2 (en) |
CA (1) | CA3046965A1 (en) |
CL (1) | CL2019001626A1 (en) |
CO (1) | CO2019006200A2 (en) |
CR (1) | CR20190282A (en) |
DK (1) | DK3555097T3 (en) |
EC (1) | ECSP19042688A (en) |
ES (1) | ES2922379T3 (en) |
HR (1) | HRP20220885T1 (en) |
HU (1) | HUE059274T2 (en) |
IL (1) | IL267275B (en) |
JO (1) | JOP20190143B1 (en) |
LT (1) | LT3555097T (en) |
MD (1) | MD3555097T2 (en) |
MX (2) | MX2022004474A (en) |
MY (1) | MY196260A (en) |
NI (1) | NI201900060A (en) |
PE (1) | PE20191105A1 (en) |
PH (1) | PH12019501254A1 (en) |
PL (1) | PL3555097T3 (en) |
PT (1) | PT3555097T (en) |
RS (1) | RS63500B1 (en) |
SA (1) | SA519402216B1 (en) |
SI (1) | SI3555097T1 (en) |
TW (1) | TWI777997B (en) |
UA (1) | UA125042C2 (en) |
WO (1) | WO2018112379A1 (en) |
ZA (1) | ZA201904615B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6744489B2 (en) | 2016-10-24 | 2020-08-19 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | 6,7,8,9-Tetrahydro-3H-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
US10294226B2 (en) | 2016-12-16 | 2019-05-21 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the JAK family of kinases |
TWI831738B (en) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES |
PT3494116T (en) | 2017-01-30 | 2020-01-28 | Astrazeneca Ab | Estrogen receptor modulators |
BR112020025605A2 (en) | 2018-06-15 | 2021-03-23 | Reata Pharmaceuticals, Inc. | pyrazole and imidazole compounds for inhibition of il-17 and rorgama |
TW202016110A (en) * | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
WO2019246461A1 (en) | 2018-06-20 | 2019-12-26 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
WO2020216936A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
JP7320628B2 (en) * | 2019-06-06 | 2023-08-03 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | Method for synthesizing furoimidazopyridine compound, crystalline form of furoimidazopyridine compound and crystalline form of salt thereof |
CN110483514B (en) * | 2019-09-16 | 2022-06-14 | 启元生物(杭州)有限公司 | Cyano-substituted cyclic hydrazine derivative and application thereof |
CA3166743A1 (en) * | 2020-02-21 | 2021-08-26 | Weiwei Mao | Crystalline forms of jak inhibitor and uses thereof |
CN116925077A (en) * | 2020-09-08 | 2023-10-24 | 一又生物(上海)有限公司 | Pyrido ring compound, and preparation method, intermediate, composition and application thereof |
KR20230156752A (en) | 2021-03-11 | 2023-11-14 | 얀센 파마슈티카 엔브이 | Lorfucitinib for use in the treatment of JAK-mediated disorders |
CN113292561A (en) * | 2021-05-22 | 2021-08-24 | 中国药科大学 | Compound with dipyrrolopyridine structure, preparation method and medical application |
CN114432317A (en) * | 2021-05-31 | 2022-05-06 | 广州嘉越医药科技有限公司 | Application of pyrrolopyrimidine compounds |
CN113861194B (en) * | 2021-11-10 | 2022-07-05 | 英维沃化工科技(广州)有限公司 | Pyrrolopyridine-containing bisamide imidazole compound and preparation method and application thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
EP1910358A2 (en) * | 2005-07-14 | 2008-04-16 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
CN102127078A (en) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Heterocyclic janus kinase 3 inhibitors |
AU2009257602B2 (en) | 2008-06-10 | 2015-10-08 | Abbvie Inc. | Novel tricyclic compounds |
JP2011066747A (en) * | 2009-09-18 | 2011-03-31 | Panasonic Corp | Surface acoustic wave filter |
PE20130005A1 (en) | 2009-12-01 | 2013-02-16 | Abbvie Inc | NEW TRICYCLIC COMPOUNDS |
PL2506716T3 (en) | 2009-12-01 | 2017-10-31 | Abbvie Inc | Novel tricyclic compounds |
MX2012008049A (en) | 2010-01-12 | 2012-08-01 | Hoffmann La Roche | Tricyclic heterocyclic compounds, compositions and methods of use thereof. |
CA2789186A1 (en) | 2010-02-10 | 2011-08-18 | Genon Biotechnologies Oy | Dual activity kinase domains and uses thereof |
WO2013007765A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
EP2924026A1 (en) * | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
CN111362975B (en) | 2015-05-28 | 2022-04-05 | 施万生物制药研发Ip有限责任公司 | Naphthyridine compounds as JAK kinase inhibitors |
WO2017079639A1 (en) | 2015-11-04 | 2017-05-11 | Mayo Foundation For Medical Education And Research | Methods and materials for treating autoimmune conditions |
JP6744489B2 (en) | 2016-10-24 | 2020-08-19 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | 6,7,8,9-Tetrahydro-3H-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
EP3528645A1 (en) | 2016-12-16 | 2019-08-28 | Société des Produits Nestlé S.A. | Oligosaccharides for flavour generation |
AU2017378060B2 (en) | 2016-12-16 | 2020-09-03 | Eli Lilly And Company | 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors |
AU2017374992A1 (en) | 2016-12-16 | 2019-06-20 | Basf Se | Pesticidal compounds |
JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
US10294226B2 (en) | 2016-12-16 | 2019-05-21 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the JAK family of kinases |
KR102466418B1 (en) | 2016-12-16 | 2022-11-14 | 화이자 인코포레이티드 | Glp-1 receptor agonists and uses thereof |
PT3494116T (en) | 2017-01-30 | 2020-01-28 | Astrazeneca Ab | Estrogen receptor modulators |
AU2018256459B2 (en) | 2017-04-21 | 2023-12-07 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
WO2020216936A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
-
2017
- 2017-12-15 US US15/843,642 patent/US10294226B2/en active Active
- 2017-12-15 TW TW106144095A patent/TWI777997B/en active
- 2017-12-15 BR BR112019011968-0A patent/BR112019011968A2/en active IP Right Grant
- 2017-12-15 EP EP17854175.1A patent/EP3555097B1/en active Active
- 2017-12-15 KR KR1020197020121A patent/KR102352462B1/en active IP Right Grant
- 2017-12-15 DK DK17854175.1T patent/DK3555097T3/en active
- 2017-12-15 CN CN201780077753.4A patent/CN110088105B/en active Active
- 2017-12-15 EP EP22178880.5A patent/EP4086256A1/en active Pending
- 2017-12-15 WO PCT/US2017/066744 patent/WO2018112379A1/en active Application Filing
- 2017-12-15 HU HUE17854175A patent/HUE059274T2/en unknown
- 2017-12-15 UA UAA201908086A patent/UA125042C2/en unknown
- 2017-12-15 HR HRP20220885TT patent/HRP20220885T1/en unknown
- 2017-12-15 ES ES17854175T patent/ES2922379T3/en active Active
- 2017-12-15 JP JP2019531668A patent/JP7291077B2/en active Active
- 2017-12-15 MY MYPI2019003389A patent/MY196260A/en unknown
- 2017-12-15 PL PL17854175.1T patent/PL3555097T3/en unknown
- 2017-12-15 SI SI201731186T patent/SI3555097T1/en unknown
- 2017-12-15 AU AU2017377069A patent/AU2017377069B2/en active Active
- 2017-12-15 PT PT178541751T patent/PT3555097T/en unknown
- 2017-12-15 PE PE2019001252A patent/PE20191105A1/en unknown
- 2017-12-15 MD MDE20191212T patent/MD3555097T2/en unknown
- 2017-12-15 LT LTEPPCT/US2017/066744T patent/LT3555097T/en unknown
- 2017-12-15 JO JOP/2019/0143A patent/JOP20190143B1/en active
- 2017-12-15 MX MX2022004474A patent/MX2022004474A/en unknown
- 2017-12-15 CA CA3046965A patent/CA3046965A1/en active Pending
- 2017-12-15 MX MX2019007073A patent/MX2019007073A/en unknown
- 2017-12-15 RS RS20220753A patent/RS63500B1/en unknown
- 2017-12-15 CR CR20190282A patent/CR20190282A/en unknown
-
2019
- 2019-01-09 US US16/243,874 patent/US10364246B2/en active Active
- 2019-02-12 US US16/274,142 patent/US11059823B2/en active Active
- 2019-02-13 US US16/275,045 patent/US10487083B2/en active Active
- 2019-06-06 PH PH12019501254A patent/PH12019501254A1/en unknown
- 2019-06-12 CL CL2019001626A patent/CL2019001626A1/en unknown
- 2019-06-12 IL IL267275A patent/IL267275B/en unknown
- 2019-06-13 SA SA519402216A patent/SA519402216B1/en unknown
- 2019-06-14 NI NI201900060A patent/NI201900060A/en unknown
- 2019-06-14 EC ECSENADI201942688A patent/ECSP19042688A/en unknown
- 2019-06-14 CO CONC2019/0006200A patent/CO2019006200A2/en unknown
- 2019-07-15 ZA ZA2019/04615A patent/ZA201904615B/en unknown
-
2020
- 2020-10-21 AU AU2020257068A patent/AU2020257068A1/en not_active Abandoned
-
2021
- 2021-06-23 US US17/355,472 patent/US20210340143A1/en active Pending
-
2022
- 2022-06-17 AU AU2022204240A patent/AU2022204240B2/en active Active
-
2023
- 2023-02-13 JP JP2023019626A patent/JP7493068B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501355A1 (en) | Small molecule inhibitors of the jak family of kinases | |
PH12019501254A1 (en) | Small molecule inhibitors of the jak family of kinases | |
PH12020551984A1 (en) | Small molecule inhibitors of the jak family of kinases | |
EA202090659A1 (en) | COMPOSITIONS CONTAINING 6- (2-HYDROXY-2-METHYLPROPOXY) -4- (6- (6 - ((6-METOXYPIRIDIN-3-YL) METHYL) -3,6-DIAZABICYCLO [3.1.1] HEPTAN-3- IL) PYRIDIN-3-YL) PYRAZOLO [1,5-a] PYRIDINE-3-CARBONITRILE | |
EA201891067A1 (en) | [1,2,4] TRIAZOLO [1,5-a] PYRIMIDIN-7-ILY COMPOUND | |
EA201991109A1 (en) | [1,2,4] TRIAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | |
PH12014502166A1 (en) | Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases | |
EA201991094A1 (en) | COMPOUNDS [1,2,4] TRIAZOLO [1,5-a] PYRIMIDINE AS PDE2 INHIBITORS | |
EA201990973A1 (en) | COMPOUNDS [1,2,4] TRIAZOLO [1,5-a] PYRIMIDINE AS PDE2 INHIBITORS | |
MX2015000336A (en) | Inhibitors of phosphodiesterase 10 enzyme. | |
EA201991473A1 (en) | IMIDAZOPYRROLOPYRIDINE AS AN INHIBITOR KINASE KINASE FAMILY JAK | |
EA201991472A1 (en) | LOW-MOLECULAR KINASE INHIBITORS JAK FAMILY | |
EA202190047A1 (en) | LOW MOLECULAR KINASE INHIBITORS OF THE JAK FAMILY | |
CR20190283A (en) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
AR114969A1 (en) | SMALL MOLECULE INHIBITORS FROM THE JAK FAMILY OF KINASES | |
MA50430B1 (en) | Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as janus kinase inhibitors |